The Anticoagulants Market is expected to register a CAGR of 9.41% during the forecast period. Anticoagulants are used to treat and prevent blood clots which can block blood vessels (an artery or a vein) that can lead to serious complications as the clot disrupts the flow of blood to important organs and can result in heart attack and stroke.
A blood clot is a seal created by the blood to stop bleeding from wounds. Most prescribed anticoagulant is warfarin. Some of the newer types of anticoagulants are edoxaban, apixaban, dabigatran, and rivaroxaban.
According to the World Health Organization (WHO), globally cardiovascular diseases (CVDs) are the number 1 cause of death, an estimated 17.9 million each year suffer from cardiovascular diseases. Four out of 5 cardiovascular deaths are due to strokes and heart attacks, and one-third of deaths occur prematurely in people under 70 years of age.
Furthermore, increasing cases of chronic diseases, unhealthy lifestyles adopted by individuals, and growing adoption of novel oral anticoagulants (NOACs) are the key driving factors in anticoagulants market.
Key Market Trends Novel Oral Anticoagulants (NOACs) Segment is Expected to Hold Significant Market Share in the Anticoagulants Market
Novel Oral Anticoagulants (NOACs) segment holds a significant market share in the anticoagulants market and is anticipated to show a similar trend over the forecast period owing to the growing adoption of the novel oral anticoagulants (NOACs) in developing countries and high preference of NOACs over the warfarin. Novel oral anticoagulants (NOACs) are a new class of anticoagulant drugs. Moreover, these are safe (lower incidence of major bleeding), convenient to use, no interactions with food, and shorter half-life. Some of the NOACs include dabigatran, rivaroxaban, apixaban, and edoxaban. These can be used in the prevention and treatment of atrial fibrillation/myocardial infarction, deep vein thrombosis (DVT) and pulmonary embolism.
According to the Centers for Disease Control and Prevention (CDC), each year in the United States approximately 900,000 people ((1 to 2 per 1,000 population) could be affected with deep vein thrombosis. Moreover, about 60,000-100,000 Americans die of deep vein thrombosis. The increasing incidences of cardiovascular disorders, venous thromboembolism (VTE), and technological advancements in the development of novel products are the key driving factors in the novel oral anticoagulants (NOACs) segment.
North America Holds the Largest Share by Revenue in the Market
North America is expected to hold a major market share in the global anticoagulants market due to the high demand for innovative products, and the increasing prevalence of cardiovascular disorders in this region. According to the American Heart Association Research, approximately 2,300 Americans die due to cardiovascular diseases each day, an average of one death every 38 seconds. Furthermore, the presence of top pharma and biotech companies that are involved in the development of therapeutics and the presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.
Competitive Landscape The Anticoagulants Market is fragmented competitive and consists of several major players. Some of the major players operating in the market include Johnson & Johnson, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, GlaxoSmithKline Plc, Aspen Holdings, Sanofi, Pfizer, Inc and Portola Pharmaceuticals, Inc.
Reasons to Purchase this report: - The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Our reports have been used by over 10K customers, including:
The major factors attributing to the growth of the biosurgery market are increasing geriatric population, rising prevalence of chronic diseases and related surgeries, and a strong focus on R&D leading to the launch of new and advanced products. The global increase in the number of geriatrics population and obese people is likely to...
Certain factors that are driving the market growth include rising healthcare expenditure, growing burden of chronic diseases and advances in drug discovery and development. The burden of chronic diseases is increasing worldwide. According to WHO, chronic diseases have always been a massive global challenge, and they account for approximately...
The global autoinjectors market is projected to reach USD 104.9 billion by 2025 from USD 46.0 billion in 2020, at a CAGR of 17.9% from 2020 to 2025. Market growth is largely driven by the growing prevalence of targeted therapies, the rising incidence of anaphylaxis, rising preference for self-administration of drugs, usability advantages,...
The Nitinol Medical Devices Market is expected to register a CAGR of 9.1% over the forecast period. Growing burden of diseases and increasing adoption of minimally invasive surgeries is expected to propel the global nitinol medical devices market growth. Nitinol known for its super-elasticity, has wide number of applications in the healthcare...
The late stage chronic kidney disease drugs market was valued at US$ 4,680.0 million in 2019 and is projected to reach US$ 11,096.9 million by 2027; it is expected to grow at a CAGR of 11.6% during 2020–2027. The growth of the late stage chronic kidney disease drugs market is mainly attributed to the factors such as high prevalence...
Global centesis catheters market is projected to grow at a CAGR of 6.8% The global centesis catheters market is projected to reach USD 633 million by 2025 from USD 426 million in 2019, growing at a CAGR of 6.8% from 2019 to 2025. The key factors driving the growth of this market include the rising target patient population...
Global Surface Disinfectant market is expected to witness a CAGR of 9.95% during the forecast period. Certain factors that are driving the market growth include rising incidence of hospital-acquired infections, growing geriatric population and subsequent growth in the prevalence of chronic diseases, and the increasing number of surgical procedures. Due...
Biochips are being increasingly used in the area of biomedical and biotechnological research. With the advancement of technology in the medical field, there has been a rise in adoption of biochips in proteomics, such as in microarrays. The advantages of protein biochips include low sample consumption and its inclination towards miniaturization....
The market for advanced medical stopcock in the Asia Pacific is expected to reach US$ 201.5 Mn in 2027 from US$ 137.9 Mn in 2018. The growth rate of the market in the region is estimated to be 4.5% during the forecast period. The growth of the market is majorly contributed by the rising prevalence of the infectious disease across the region...
84 pages •
By The Business Research Company
• Jun 2019
Portable Ultrasound Devices Market Report 2019 provides the strategists, marketers and senior management with the critical information they need to assess the global portable ultrasound devices market. Description: Where is the largest and fastest growing market for the portable ultrasound devices...
Research And Development
Public Health Insurance
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.